Notably, 15% or 30% of 4TO7-Brca–KO cells with Gsdmc-WT expression were sufficient to reduce tumor growth in response to PARPi treatment (Figure 2H), indicating GSDMC-mediated potent antitumor immunity. This evidence concerns the gene GSDMC and neoplasm.